Company news

Myriad Genetics, Inc. news in 2026

Myriad Genetics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives

November 4, 2026

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

November 2, 2026

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

October 22, 2026

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

October 20, 2026

Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026

October 15, 2026

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

October 8, 2026

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

October 8, 2026

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

September 16, 2026

Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

August 27, 2026

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

July 30, 2026

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

July 23, 2026

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

July 21, 2026

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

July 1, 2026

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

June 23, 2026

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

June 2, 2026

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

May 27, 2026

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

May 26, 2026

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

May 15, 2026

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

May 7, 2026

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

May 5, 2026

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

April 30, 2026

ProgenyHealth Announces New Appointments to Company Leadership Board and Executive Team

April 29, 2026

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

April 28, 2026

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

April 16, 2026

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

April 13, 2026

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

April 8, 2026

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

March 17, 2026

Myriad Commercially Launches Precise MRD with Select Community Oncologists

March 2, 2026

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

February 23, 2026

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

February 23, 2026

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

February 19, 2026

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

February 16, 2026

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

January 27, 2026

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

January 12, 2026

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026